Sanctuary Advisors LLC Acquires 667 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sanctuary Advisors LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.2% during the third quarter, Holdings Channel.com reports. The firm owned 16,613 shares of the medical equipment provider’s stock after buying an additional 667 shares during the period. Sanctuary Advisors LLC’s holdings in Hologic were worth $1,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. TD Private Client Wealth LLC lifted its stake in shares of Hologic by 2,374.4% during the third quarter. TD Private Client Wealth LLC now owns 4,825 shares of the medical equipment provider’s stock valued at $393,000 after acquiring an additional 4,630 shares during the period. Toronto Dominion Bank grew its position in shares of Hologic by 19.2% during the 3rd quarter. Toronto Dominion Bank now owns 115,232 shares of the medical equipment provider’s stock worth $9,387,000 after buying an additional 18,526 shares during the period. Coldstream Capital Management Inc. raised its stake in shares of Hologic by 56.3% during the third quarter. Coldstream Capital Management Inc. now owns 9,410 shares of the medical equipment provider’s stock worth $761,000 after buying an additional 3,388 shares during the last quarter. M&T Bank Corp boosted its stake in Hologic by 0.8% in the third quarter. M&T Bank Corp now owns 26,368 shares of the medical equipment provider’s stock valued at $2,148,000 after acquiring an additional 201 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after acquiring an additional 231,578 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 1.3 %

Hologic stock opened at $71.65 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52 week low of $70.36 and a 52 week high of $84.67. The stock has a 50-day simple moving average of $78.65 and a 200 day simple moving average of $78.52. The stock has a market capitalization of $16.26 billion, a P/E ratio of 21.52, a PEG ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 earnings per share. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on HOLX. Leerink Partners dropped their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. UBS Group raised their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada boosted their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.